April 19, 2024

• 

[THE INVESTOR] Samsung BioLogics said on Oct. 19 that it has been included in Fortune’s Future 50 list of companies with strong future growth prospects.

Fortune, in partnership with Boston Consulting Group, has selected Future 50 since last year to pick 50 global companies every year with the best prospects for long-term growth.

Among the listed companies are Alphabet, Netflix and China-based Alibaba Group Holding.

“Fortune Future 50 again proves Samsung BioLogics’ growth potential in the global market,” said CEO Kim Tae-han in a press release. “The company will continue to make full efforts to grow into the leading global  biopharmaceutical drug development and manufacturing company that can help not only customers but also patients.”

Samsung BioLogics currently manufactures products for prominent global pharmaceutical brands, such as US-based Bristol-Myers Squibb and Switzerland-based Roche Holding. The company is at the forefront of Samsung Group’s quest for new growth engines.

By Song Seung-hyun and newswires (ssh@heraldcorp.com)